Bellevue Life Sciences Acquisition CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OSR Health, Inc. reported a net loss of $1.0 million for Q2 2026, with significant decreases in net sales and ongoing operational losses, while also highlighting efforts to secure additional capital.
OSR Holdings reported a 36% decrease in net sales for Q1 2026, but saw gross profit margins improve to 33% due to a shift to a consignment model.
OSR Holdings, Inc. reported increased operating and net losses for the nine months ended September 30, 2025, driven by public company costs and merger expenses, while announcing a strategic acquisition and ongoing capital raises.
OSR Holdings, Inc. reported increased losses for the first half of 2025 due to merger-related expenses, while advancing strategic initiatives including a new acquisition and equity tokenization plans.
OSR Holdings' Q1 2025 net sales decreased by 16% compared to Q1 2024, primarily due to the termination of a key customer relationship.
10-Q: Bellevue Life Sciences Acquisition Corp. Reports Q3 2024 Results, Faces Ongoing Listing Challenges
Bellevue Life Sciences Acquisition Corp. reported a net loss for the third quarter of 2024 and is navigating ongoing challenges with Nasdaq listing requirements while pursuing a business combination.
Bellevue Life Sciences Acquisition Corp. reported a net loss for the second quarter of 2024 and is facing substantial doubt about its ability to continue as a going concern due to liquidity issues.
Bellevue Life Sciences Acquisition Corp. reported a net loss for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.